Page last updated: 2024-11-02

pd 153035 and Lung Neoplasms

pd 153035 has been researched along with Lung Neoplasms in 11 studies

4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline: structure given in first source
PD-153035 : A member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7.

Lung Neoplasms: Tumors or cancer of the LUNG.

Research Excerpts

ExcerptRelevanceReference
"Gefitinib is an EGFR-TK inhibitor that is clinically used to treat NSCLC; however, this drug frequently causes adverse effects, including skin eruptions."1.36Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes. ( Muro, Y; Shimoyama, Y; Sugiura, K; Tomita, Y; Yamaki, M, 2010)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (45.45)29.6817
2010's6 (54.55)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Qin, X1
Li, Z1
Yang, L1
Liu, P1
Hu, L1
Zeng, C1
Pan, Z1
Zhang, GN1
Zhang, YK1
Wang, YJ1
Gupta, P1
Ashby, CR1
Alqahtani, S1
Deng, T1
Bates, SE1
Kaddoumi, A1
Wurpel, JND1
Lei, YX1
Chen, ZS1
Xin, HW1
Yang, JH1
Nguyen, DM1
Dai, D1
Li, XF1
Wang, J1
Liu, JJ1
Zhu, YJ1
Zhang, Y1
Wang, Q1
Xu, WG1
Liu, N1
Li, M1
Li, X1
Meng, X2
Yang, G2
Zhao, S2
Yang, Y1
Ma, L2
Fu, Z1
Yu, J3
Pantaleo, MA1
Nannini, M1
Fanti, S1
Boschi, S1
Lollini, PL1
Biasco, G1
Yamaki, M1
Sugiura, K1
Muro, Y1
Shimoyama, Y1
Tomita, Y1
Loo, BW1
Murphy, JD1
Sun, X2
Wang, H1
Song, X1
Mu, D1
Xiong, X1
Fu, L1
Wang, L1
Cai, H1
Li, L1
Jiang, H1
Duan, W1
Mei, C1
Lichtner, RB1
Menrad, A1
Sommer, A1
Klar, U1
Schneider, MR1

Other Studies

11 other studies available for pd 153035 and Lung Neoplasms

ArticleYear
Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant.
    Bioorganic & medicinal chemistry, 2016, 07-01, Volume: 24, Issue:13

    Topics: A549 Cells; Antineoplastic Agents; Cell Proliferation; Drug Discovery; ErbB Receptors; Humans; Inhib

2016
Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo.
    Cancer letters, 2018, 06-28, Volume: 424

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Ce

2018
Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor requires E-cadherin in esophageal cancer and malignant pleural mesothelioma.
    Anticancer research, 2013, Volume: 33, Issue:6

    Topics: Biomarkers, Tumor; Cadherins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzym

2013
Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.
    International journal of cancer, 2016, Feb-15, Volume: 138, Issue:4

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Carbon Radioisotopes; Carcinoma, Non-Small-Cell L

2016
PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2009, Volume: 50, Issue:2

    Topics: Adult; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Ligands

2009
Molecular imaging of EGFR: it's time to go beyond receptor expression.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2009, Volume: 50, Issue:7

    Topics: Adult; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Ligands

2009
Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes.
    Experimental dermatology, 2010, Volume: 19, Issue:8

    Topics: Acneiform Eruptions; Adolescent; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control

2010
Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011, Volume: 52, Issue:10

    Topics: Aged; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; E

2011
Assessment of 11C-labeled-4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression.
    Cancer science, 2007, Volume: 98, Issue:9

    Topics: Animals; Biomarkers, Tumor; Carbon Radioisotopes; Cell Line, Tumor; ErbB Receptors; Female; Humans;

2007
Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo.
    Investigational new drugs, 2009, Volume: 27, Issue:1

    Topics: Adenocarcinoma; Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line,

2009
Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
    Cancer research, 2001, Aug-01, Volume: 61, Issue:15

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Division; Enzyme In

2001